ATRC amends 8-K for signature; cites Q3 2025 press release

Rhea-AI Filing Summary

AtriCure, Inc. (ATRC) filed an Amendment No. 1 to its Form 8-K to add the required signature of a duly authorized representative. The amendment makes no other changes to the original report filed on October 29, 2025.

The company also noted it issued a press release regarding financial results for the third quarter ended September 30, 2025, and scheduled a conference call on October 29, 2025 at 4:30 p.m. Eastern Time. The press release is furnished as Exhibit 99.1.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001323885True8KA conformed signature00013238852025-10-292025-10-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K/A

AMENDMENT NO. 1

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) of the

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 29, 2025

AtriCure, Inc.

(Exact name of registrant as specified in charter)

Delaware			000-51470			34-1940305
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification No.)

7555 Innovation Way, Mason OH 45040

(Address of Principal Executive Offices, and Zip Code)

(513) 755-4100

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $.001 par value			ATRC			NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Explanatory Note

This Amendment No. 1 to Form 8-K is filed because the original Form 8-K filing did not include the signature of a duly authorized representative of the Registrant. This Amendment No. 1 includes the required signature and makes no other change to the original Form 8-K filed on October 29, 2025.

Item 2.02.    Results of Operations and Financial Condition.

On October 29, 2025, AtriCure, Inc. issued a press release regarding its financial results for the third quarter ended September 30, 2025. The Company will hold a conference call on October 29, 2025 at 4:30 p.m. Eastern Time to discuss the financial results. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

The information in Item 2.02 of Form 8-K and in the press release attached as Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in each of Item 2.02 of this Form 8-K and Exhibit 99.1 shall not be incorporated by reference in any filing or other document under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing or document.

Item 9.01.    Financial Statements and Exhibits.

(d)Exhibits

No.						Description
99.1						Press Release dated October 29, 2025, relating to financial results for the third quarter ended September 30, 2025.
104						Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						ATRICURE, INC.
Dated:			October 29, 2025			By:			/s/ Angela L. Wirick
									Angela L. Wirick
									Chief Financial Officer

FAQ

What did AtriCure (ATRC) change with this 8-K/A?

The amendment adds the required signature of a duly authorized representative and makes no other changes to the original report filed on October 29, 2025.

Does this 8-K/A include AtriCure’s Q3 2025 results?

It references and furnishes a press release for the third quarter ended September 30, 2025 as Exhibit 99.1.

When is AtriCure’s conference call for Q3 2025 results?

October 29, 2025 at 4:30 p.m. Eastern Time.

Is the Q3 2025 press release considered filed or furnished?

It is furnished under Item 2.02 and not deemed filed for purposes of Section 18 of the Exchange Act.

Who signed the amended report for AtriCure?

Angela L. Wirick, Chief Financial Officer, signed the report.

What exhibit numbers are included in this filing?

Exhibit 99.1 (press release dated October 29, 2025) and Exhibit 104 (cover page Inline XBRL tags).